N2OFF, Inc. /
MitoCareX Bio Ltd.
N2OFF completes merger with cancer drug discovery company MitoCareX Bio Ltd.
Source for the buyer and target: N2OFF, Inc.
For the buyer and target.
“Neve Yarak, Israel, October 23, 2025 (GLOBE NEWSWIRE) – N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio Ltd . (“MitoCareX”), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family.”
Published 23 Oct 2025
Open the sourceWhat happened
N2OFF, Inc. closed its merger with MitoCareX Bio Ltd., a biotech company focused on drug discovery targeting cancer therapeutics. The transaction made MitoCareX a wholly-owned subsidiary of N2OFF. [01]
N2OFF paid SciSparc $700,000 in cash and issued N2OFF common stock as consideration for shares in MitoCareX. [01]
The source
Everything on this page comes from the source below, quoted word for word.
N2OFF completes merger with cancer drug discovery company MitoCareX Bio Ltd.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly